Success Metrics

Clinical Success Rate

83.3%

Based on 10 completed trials

Completion Rate

83%(10/12)

Active Trials

1(5%)

Results Posted

20%(2 trials)

Terminated

2(11%)

Phase Distribution

Ph phase_2

11%

Ph not_applicable

11%

Ph phase_3

11%

Ph phase_4

53%

Ph phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution17 total trials

Phase 1Safety & dosage

1(5.9%)

Phase 2Efficacy & side effects

2(11.8%)

Phase 3Large-scale testing

2(11.8%)

Phase 4Post-market surveillance

10(58.8%)

N/ANon-phased studies

2(11.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(10)

Terminated(2)

Other(6)

Detailed Status

Completed10

unknown6

Terminated2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (5.9%)

Phase 22 (11.8%)

Phase 32 (11.8%)

Phase 410 (58.8%)

N/A2 (11.8%)

Trials by Status

unknown632%

completed1053%

terminated211%

recruiting15%

Recent Activity

1 active trials

Showing 5 of 19

terminatedphase_4

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

NCT03012360

recruitingphase_2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

NCT04310930

completedphase_1

Evaluation of Innovative Tools in Development of Antibiotics

NCT03177720

unknownnot_applicable

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

NCT04208763

completed

The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients

NCT03308214

View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials

NCT03012360Phase 4

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Terminated

NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting

NCT03177720Phase 1

Evaluation of Innovative Tools in Development of Antibiotics

Completed

NCT04208763Not Applicable

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Unknown

NCT03308214

The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients

Completed

NCT03858387

PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

Unknown

NCT02493764Phase 3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Completed

NCT01659866Phase 4

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Completed

NCT03776305Phase 4

Imipenem in Critically Ill Patients

Unknown

NCT03733340Phase 2

Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT

Unknown

NCT01379157Phase 4

Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia

Completed

NCT02474706Phase 4

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Terminated

NCT02897206Phase 4

Imipenem Prophylaxis in Patients With Acute Pancreatitis

Completed

NCT02616354Phase 4

Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin

Unknown

NCT01820026Phase 4

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

Unknown

NCT02213783Phase 4

Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia